J Korean Ophthalmol Soc.  2009 Jan;50(1):27-33. 10.3341/jkos.2009.50.1.27.

Long-term Evaluation After Topical Cyclosporine Treatment in Dry Eye Patients With Graft-Versus-Host Disease

• Lee SH
• Im SK
• Woo JM
• Yoon KC

• KMID: 2211894
• DOI: http://doi.org/10.3341/jkos.2009.50.1.27

Abstract

PURPOSE
This study was performed to evaluate the long-term effect of 0.05% cyclosporine A emulsion (Restasis, Allergan Inc. USA.) on dry eye associated with graft-versus-host disease (GVHD).
METHODS
Sixteen eyes of 8 patients with severe dry eye associated with GVHD were treated with 0.05% cyclosporine A emulsion twice a day. Tear film parameters were evaluated before treatment and after 1, 3, 6, and 12 months of treatment.
RESULTS
One month after treatment, tear break-up time improved from 3.88+/-1.78 s to 4.17+/-1.90 s (P=0.02). Three months after treatment, symptom score and basal secretion improved from 3.00+/-0.38 and 4.44+/-1.59 mm to 2.33+/-0.52 (P=0.04) and 5.42+/-2.50 mm (P=0.04), respectively. Twelve months after treatment, the keratoepitheliopathy score improved from 2.38+/-1.31 to 1.13+/-0.35 (P=0.02).
CONCLUSIONS
Use of a 0.05% cyclosporine A emulsion is effective for dry eye associated with GVHD as it helps to increase tear secretion and to relieve symptoms. Treatment with 0.05% cyclosporine A emulsion for longer than 1 year may be necessary to improve keratoepitheliopathy.

Keyword

Cyclosporine; Dry eye syndrome; Graft-versus-host disease

MeSH Terms

Cyclosporine
Dry Eye Syndromes
Eye
Graft vs Host Disease
Humans
Tears
Cyclosporine

Figure

• 

  Figure 1. Slit lamp photographs with fluorescein staining in GVHD patient with dry eye syndrome before (A) and 1 year after (B) 0.05% cyclosporine A therapy. Note the marked improvement in the corneal epithelium.

Reference

References

1. Horowitz M. Uses and growth of hematopoietic cell trans- plantation immunology. Blume KG, Forman SJ, Applebaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. 3rd. Blackwell: Malden, MA;2004. v. 1 chap. 2.

2. Martin PJ. Overview of hematopoietic cell transplantation. Blume KG, Forman SJ, Applebaum FR, editors. Thomas’ Hematopoietic Cell Transplantation. 3rd. Blackwell: Malden, MA;2004. v. 1 chap. 3.

3. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003; 22:19–27.

4. Franklin RM, Kenyon KR, Tutschka PJ. . Ocular mani- festations of graft-vs-host disease. Ophthalmology. 1983; 90:4–13.

5. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2004; 15:503–7.

6. Johnson DA, Jabs DA. The ocular manifestations of graft- versus-host diseases. Int Ophthalmol Clin. 1997; 37:119–33.

7. Ogawa Y, Okamoto S, Wakui M. . Dry eye after hematopoietic stem cell transplantation. Br J Ophthalmol. 1999; 83:1125–30.

8. Ogawa Y, Okamoto S, Mori T. . Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003; 31:579–83.

9. Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant. 1996; 18:641–2.

10. RochaEM, Pelegrino FS, de Paiva CS. . GVHD dry eyestreated with autologous serum tears. Bone Marrow Transplant. 2000; 25:1101–3.

11. Ogawa Y, Okamoto S, Kuwana M. . Successful treatment of dry eye in two patients with chronic graft versus host disease with systemic administration of FK506 and corticos-teroids. Cornea. 2001; 20:430–4.

12. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000; 19:644–9.

13. Nussenblatt RB, Palestine AG. Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986; 31:159–69.

14. Hemady R, Tauber J, Foster SC. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991; 35:369–85.

15. Jabs DA, Wingard J, Green R. . The eye in bone marrow transplantation. Arch Ophthalmol. 1989; 107:1343–8.

16. Bhan AK, Fujikawa LS, Foster CS. T-cell subsets and Langer- hans cells in normal and diseased conjunctiva. Am J Ophthal-mol. 1982; 94:205–12.

17. Gilbard JP, Rossi SR, Azar DT, Heyda KG. Effect of punctual occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorder. CLAO J. 1989; 15:216–8.

18. Lee EH, Jang JW, Lew HM. The changes of tear osmolarity and protein after silicone punctal plug insertion in dry eye. J Korean Ophthalmol Soc. 2001; 42:1509–14.

19. Yen MT, Pflucfelder SC, Feuer WJ. The effect of punctual occlusion on tear production, tear clearance and ocular surface sensation in normal subjects. Am J Ophthalmol. 2001; 131:314–23.

20. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-β2 production. Cornea. 2008; 27:64–9.

21. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007; 114:76–9.

22. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007; 26:805–9.

23. Salib GM, McDonald MB, Smolek M. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis. J Cataract Refract Surg. 2006; 32:772–8.

24. Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005; 89:1363–7.

25. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000; 107:631–9.

26. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporine A phase 2 study group. Ophthal-mology. 2000; 107:967–74.

27. Lelli GJ Jr, Musch DC, Gupta A. . Ophthalmic cyclosporine use in ocular GVHD. Cornea. 2006; 25:635–8.

28. Wang Y, Ogawa Y, Dogru M. . Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2008; 41:293–302.

29. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005; 112:1790–4.

30. Sall K, Stevenson OD, Mundorf TK, Reis BL. CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000; 107:631–9.

31. Stevenson D, Tauber J, Reis BL. The Cyclosporine A Phase 2 Study Group. Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderate to severe dry eye syndrome: a dose-ranging, randomized trial. Ophthal-mology. 2000; 107:967–74.

32. Djalilian AR, Nussenblatt RB, Holland EJ. Immuno-suppressive therapy in ocular surface transplantation. Holland EJ, Mannis MJ, editors. Ocular surface disease Medical and surgical management. 1st. New York: Springer;2002. v. 1. chap. 22.

33. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res. 1998; 17:565–96.

34. Kaido M, GotoE, Dogru M, Tsubota K. Punctal occlusion for Stevens-Johnson syndrome. Ophthalmology. 2004; 111:895–900.

35. Stern ME, Geo J, Siemasko KT. . Role of the lacrimal gland functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004; 78:409–16.

36. Pepose JS, Akata RF, Pflugfelder SC, Voigt W. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjogren's syndrome. Ophthalmology. 1990; 97:1599–605.

37. Poon AC, Geerling G, Dart JK. . Autologous serum eyedrops for dry eye and epithelial defect: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001; 85:1188–97.

38. Hirst LW, Jabs DA, Tutschka PJ. . The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol. 1983; 101:580–4.

39. Shulman HM, Sullivan KM, Weiden PL. . Chronic graft- versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980; 69:204–17.

40. Mencucci R, Rossi Ferrini C, Bosi A. . Ophthalmological aspects in allogenic bone marrow transplantation: Sjogren-like syndrome in graft-versus-host disease. Eur J Ophthalmol. 1997; 7:13–8.

41. Tichelli A, Duell T, Weiss M. . Late-onset keratoconjunc- tivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European group for blood and marrow transplantation (EBMT) Working party on late effects. Bone Marrow Transplant. 1996; 17:1105–11.

42. Ogawa Y, Kuwana M, Yamazaki K. . Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versushost disease. Invest Ophthalmol Vis Sci. 2003; 44:1888–96.

43. Ogawa Y, Yamazaki K, Kuwana M. . A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci. 2001; 42:111–9.

44. Yoon KC, Jeong IY, Im SK. . Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transplant. 2007; 3:231–5.

45. Vajpayee RB, Mukerji N, Tandon R. . Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br J Ophthalmol. 2003; 87:1312–6.

46. Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporine A 0.05% eyedrops. Cornea. 2007; 26:1035–8.

47. Pucci N, Massi C, Bernardini R. . Eyelash length in children with verna keratoconjunctivitis: effect of treatment with cyclosporine eye drops. Int J Immunopathol Pharmacol. 2007; 20:595–9.

48. Doan S, Gabison E, Abitbol O. . Efficacy of topical 2% cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis. J Fr Ophtalmol. 2007; 30:697–701.

49. Kiliç A, Gürler B. Topical 2% cyclosporine A in preservativefree artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006; 41:693–8.

50. Reinhard T, Sundmacher R. Local cyclosporin A therapy in Thygeson superficial punctate keratitis--a pilot study. Klin Monatsbl Augenheilkd. 1996; 209:224–7.

51. Rubin M, Rao SN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther. 2006; 22:47–53.

52. Perry HD, Doshi-Carnevale S, Donnenfeld ED. . Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006; 25:171–5.

53. Sahin A, Bozkurt B, Irkec M. Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up. Cornea. 2008; 27:193–5.

54. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Kornstein HS. Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis Ophthalmology. 2003; 110:1578–81.